Press releases

8
Apr 2024
09:37 E.S.T.

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Read more
16
Jan 2024
21:30 E.S.T.

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Read more
22
Dec 2023
21:30 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Read more
17
Nov 2023
21:30 E.S.T.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Read more
15
Nov 2023
07:30 E.S.T.

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Read more
6
Nov 2023
21:30 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Read more
2
Nov 2023
20:30 E.S.T.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Read more
1
Nov 2023
20:30 E.S.T.

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Read more
1
Nov 2023
07:00 E.S.T.

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Read more
31
Oct 2023
20:30 E.S.T.

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US